Tag: growth

More great news before Christmas! We are happy to announce the appointment of Dr. Maria Lahtinen as the Chief Development Officer. Dr. Lahtinen has diligently served as the company’s Quality Director for the past year. The company’s CEO, Dr. Maksimow, expressed his excitement, stating, “I am thrilled to have Maria as our CDO, especially as we progress SAR003, […]

The board of Sartar Therapeutics Oy is delighted to announce Dr. Mikael Maksimow as the new CEO of the company. Dr. Maksimow officially assumed his role on December 7th, following more than two years of dedicated service as Sartar’s Chief Operating Officer. “We are excited to have Mikael, a seasoned, dynamic, and innovative CEO, spearheading […]

We are happy to announce Mikael Maksimow has joined our team as a COO. Welcome Mikael! Mikael has broad experience in drug development from innovations to international clinical trials. His experience in advancing start-up companies will be a great addition to our small but efficient team. 

We warmly wecome Katja to the company! She is a passionate innovator with solid background in pharmaceutics, product development and startups.

Sartar’s investment round closed ahead of time on Monday (19.10.2020). We achieved incredible outcome of 2 300 000 euros just in six days. Sartar wishes to thank all investors for taking part in the round. We would also like to thank Springvest, for helping us to achieve this goal. Thank you!

Sartar was awarded a patent in Japan for the use of anagrelide in cancer therapy.

Sartar strengthens the board of directors. CEO of Herantis Pharma, Pekka Simula, has been appointed as a new member to the Sartar Therapeutics board of directors.

Sartar was awarded a U.S. patent for use of anagrelide in cancer therapy.